XML 64 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
SELECTED QUARTERLY INFORMATION - UNAUDITED
 12 Months Ended
Dec. 31, 2014
Selected Quarterly Financial Information [Abstract]  
SELECTED QUARTERLY INFORMATION - UNAUDITED
SELECTED QUARTERLY INFORMATION - UNAUDITED
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
(In thousands, except per share data)
Total revenue, net:
 
 
 
 
 
 
 
2014
$
215,059

 
$
231,351

 
$
229,719

 
$
252,176

2013 (As adjusted)*
196,652

 
205,547

 
213,246

 
220,769

Gross margin:
 
 
 
 
 
 
 
2014
$
132,676

 
$
144,375

 
$
143,745

 
$
154,708

2013 (As adjusted)*
117,040

 
123,718

 
131,479

 
136,932

Net income (loss):
 
 
 
 
 
 
 
2014
$
2,206

 
$
4,825

 
$
9,807

 
$
17,166

2013 (As adjusted)* (1)
(6,028
)
 
1,520

 
(30,330
)
 
13,771

Basic net income (loss) per common share (2):
 
 
 
 
 
 
 
2014
$
0.07

 
$
0.15

 
$
0.30

 
$
0.53

2013 (As adjusted)*
(0.22
)
 
0.05

 
(1.09
)
 
0.46

Diluted net income (loss) per common share (2):
 
 
 
 
 
 
 
2014
$
0.07

 
$
0.15

 
$
0.30

 
$
0.52

2013 (As adjusted)*
(0.22
)
 
0.05

 
(1.09
)
 
0.45


*See Note 2 of these consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.
(1) The first quarter of 2013 was negatively impacted by a voluntary recall of certain products manufactured in the Company's Añasco, Puerto Rico facility.
On July 31, 2013, the Company performed the annual goodwill impairment test which resulted in a non-cash goodwill impairment charge of $46.7 million for its U.S. Spine reporting unit, which is a part of the U.S. Spine and Other reportable segment.
The Company incurred incremental costs related to the implementation of its global enterprise resource planning system in the first, second, third, and fourth quarters of 2013 of $6.1 million, $7.6 million, $5.0 million and $5.6 million, respectively.

The Company incurred costs related to the remediation of the FDA warning letters at its manufacturing facilities of $2.1 million, $3.0 million, $2.8 million and $0.4 million in the first, second, third and fourth quarters of 2013, respectively.
(2) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing shares of its common stock during the year.